Effect of the MDM2 Promoter Polymorphisms SNP309T>G and SNP285G>C on the Risk of Ovarian Cancer in BRCA1 Mutation Carriers

BMC Cancer - United Kingdom
doi 10.1186/1471-2407-12-454
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2007English

The MDM2 Promoter Polymorphism SNP309T->G and the Risk of Uterine Leiomyosarcoma, Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck

Journal of Medical Genetics
Genetics
2005English

Physical Activity and the Risk of Breast Cancer in BRCA1/2 Mutation Carriers

Breast Cancer Research and Treatment
Cancer ResearchOncology
2009English

Body Weight and Risk of Breast Cancer in BRCA1/2 Mutation Carriers

Breast Cancer Research and Treatment
Cancer ResearchOncology
2010English

Plasma Osteoprotegerin and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Oncotarget
Oncology
2016English

Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality

JAMA - Journal of the American Medical Association
Medicine
2010English

Prevalence of the BRCA1 Founder Mutation C.5266dupin Brazilian Individuals At-Risk for the Hereditary Breast and Ovarian Cancer Syndrome

Hereditary Cancer in Clinical Practice
OncologyGenetics
2011English

Oral Contraceptive Use and Ovarian Cancer Risk Among Carriers of BRCA1 or BRCA2 Mutations

British Journal of Cancer
Cancer ResearchOncology
2004English

Uterine Cancer in Jewish Israeli BRCA1/BRCA2 Mutation Carriers

Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy